Skip to main content

Advertisement

Table 2 Change in outcomes between start of treatment and three months

From: Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial

Outcomes Treatment course: MTX Treatment course: PBO Pvalue
(N = 25) (N = 21)
DAS44 −0.08 [−0.6, 0.1] −0.13 [−0.6, 0.1] 0.44
Number of tender joints [0 – 44] 0 [−1.0, 1.3] −1 [−3.5, 0.5] 0.17
Number of swollen joints [0 – 44] −1 [−3.5, 0] 0 [−1.5, 2.0] 0.56
CRP level 0.2 [−0.8, 1.9] −0.3 [−1.6, 1.6] 0.33
Number of analgesic pills/week, median 0 [−7, 4] 0 [−2.0, 1.5] 0.36
Number of flares/3 months 0 [−1, 0] 0 [−1, 0] 0.10
VAS Pain −1 [−2.8, 0] 0 [−2, 1] 0.43
  1. All results are displayed in medians [interquartile ranges]. MTX, methotrexate; PBO, placebo; DAS44, disease activity score based on 44 joints; CRP, C-reactive protein; VAS Pain, visual analog scale for pain.